SCHEMBL1930951

SCHEMBL1930951

CC12CC3CC(CC(C3)C1(C)Br)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 3/20 0.35
GRIN3B O60391 3/20 0.35
GRIN1 Q05586 3/20 0.35
GRIN2A Q12879 3/20 0.35
GRIN2B Q13224 3/20 0.35
GRIN2C Q14957 3/20 0.35
GRIN3A Q8TCU5 3/20 0.35
SLC22A2 O15244 2/20 0.33
SLC47A1 Q96FL8 2/20 0.33
LMNA P02545 2/20 0.33
SLC22A1 O15245 1/20 0.33
TSHR P16473 1/20 0.33
NFKB1 P19838 1/20 0.33
STAT6 P42226 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
POLB P06746 1/20 0.32
THRB P10828 1/20 0.32
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL811709 0.76 GRIN2D (0.36) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Ammonia Solution, Strong SCHEMBL3787685 0.74 GRIN2D (0.35) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Water SCHEMBL27943536 0.74 GRIN2D (0.35) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Bromide SCHEMBL28280728 0.74 GRIN2D (0.35) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL8775129 0.72 GRIN2D (0.33) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Iodide SCHEMBL529148 0.72 GRIN2D (0.33) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Fluoride SCHEMBL29040384 0.72 GRIN2D (0.33) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1200522 0.72 LMNA (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL20526370 0.72 GRIN2D (0.33) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Ammonia Solution, Strong SCHEMBL528152 0.72 GRIN2D (0.33) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1267403-C Namenda synthesis method BEIJING ACADEMY OF MILITARY ME (CN) 2006-08-02 CN claimed
CN-1544415-A Namenda synthesis method 中国人民解放军北京军医学院 2004-11-10 CN claimed
EP-2091999-B1 NOVEL NANOPARTICLE CONTAINING SILOXANE POLYMERS PIBOND OY (FI) 2020-08-12 EP disclosed
EP-1891145-B1 METHOD FOR PRODUCING A POLYMER FOR SEMICONDUCTOR OPTOELECTRONICS COMPRISING POLYMERIZING FUNCTIONALIZED SILANE MONOMERS WITH BRIDGING HYDROCARBON GROUP PIBOND OY (FI) 2017-08-09 EP disclosed
EP-1891146-B1 ORGANO FUNCTIONALIZED SILANE MONOMERS AND SILOXANE POLYMERS OF THE SAME SILECS OY (FI) 2015-01-14 EP disclosed
US-20140217539-A1 SEMICONDUCTOR OPTOELECTRONICS DEVICES SILECS OY (FI) 2014-08-07 US disclosed
US-20130193543-A1 SEMICONDUCTOR OPTOELECTRONICS DEVICES SILECS OY (FI) 2013-08-01 US disclosed
CN-102942490-A Synthesis of memantine hydrochloride SHAANXI ARK PHARMACEUTICAL CO LTD 2013-02-27 CN disclosed
US-7955660-B2 Silane monomers and siloxane polymers for semiconductor optoelectronics SILECS OY (FI) 2011-06-07 US disclosed
US-7833820-B2 Nanoparticle containing siloxane polymers SILECS OY (FI) 2010-11-16 US disclosed
US-20100137448-A1 Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists NEUROMOLECULAR, INC. 2010-06-03 US disclosed
US-6620845-B2 For therapy and prophylaxis of neurological diseases NEUROMOLECULAR, INC. 2003-09-16 US disclosed
US-20030008889-A1 Aminoadamantane derivatives as therapeutic agents PANORAMA RESEARCH, INC. 2003-01-09 US disclosed
EP-1259477-A1 AMINOADAMANTANE DERIVATIVES AS THERAPEUTIC AGENTS PANORAMA RESEARCH, INC. (US) 2002-11-27 EP disclosed
US-6444702-B1 CENTRAL NERVOUS SYSTEM DISORDERS NEUROMOLECULAR, INC. 2002-09-03 US disclosed
WO-2001062706-A1 AMINOADAMANTANE DERIVATIVES AS THERAPEUTIC AGENTS PANORAMA RESEARCH, INC. (US) 2001-08-30 WO disclosed
EP-0053621-B1 UNSATURATED ESTERS OF ADAMANTANE CONTAINING DIOLS AND THERMO-RESISTANT CROSS-LINKED POLYMERS THEREFROM BATTELLE MEMORIAL INSTITUTE (CH) 1984-07-25 EP disclosed
EP-0053621-A1 UNSATURATED ESTERS OF ADAMANTANE CONTAINING DIOLS AND THERMO-RESISTANT CROSS-LINKED POLYMERS THEREFROM. BATTELLE MEMORIAL INSTITUTE (CH) 1982-06-16 EP disclosed
US-4332964-A Unsaturated esters of adamantane containing diols and thermo-resistant cross-linked polymers therefrom BATTELLE DEVELOPMENT CORPORATION (US) 1982-06-01 US disclosed
WO-1981003657-A1 UNSATURATED ESTERS OF ADAMANTANE CONTAINING DIOLS AND THERMO-RESISTANT CROSS-LINKED POLYMERS THEREFROM BATTELLE MEMORIAL INSTITUTE (CH) 1981-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137448-A1 Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists GRIN2A, GRIN1, GRIN3A GRIN2D 8/4885GRIN3B 9/4885GRIN1 2/4885
US-20030008889-A1 Aminoadamantane derivatives as therapeutic agents CHRNA4, CHRNA10, BACE1 GRIN2D 163/4885GRIN3B 251/4885GRIN1 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.